Skip to Main Content

Paper Details

p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Mol Cancer Ther
0
2022
Author NameAffiliation
Alex LookDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 1

Datasets

Release 1.2